Hematology/Oncology

Top Story

Tumor size linked to efficacy of lobectomy, segmentectomy for NSCLC

August 29, 2016

Lobectomy prolonged survival compared with sublobar resection for patients with T1a NSCLC tumors that were 2 cm or smaller, according to the results of a SEER analysis.

Patients who cannot undergo lobectomy — those with tumors between 1 cm and 2 cm — should undergo segmentectomy. Patients with tumors 1 cm or smaller have the option of segmentectomy or wedge resection, depending on patient profile and the physician’s surgical skills.

In the Journals

Majority of clinicians overestimate harms, benefits of treatment

August 29, 2016
Most resident and attending internal medicine physicians overestimated both the benefits and harms of common medical tests and treatments, according to findings…
In the Journals Plus

Early treatment shows long-term benefit for high-risk smoldering myeloma

August 29, 2016
Early treatment with lenalidomide plus dexamethasone prolonged time to progression and OS compared with observation for patients with high-risk smoldering multiple…

Extended work hours increase risk for cancer among U.S. women

August 29, 2016
Women in the United States who worked at least 60 hours per week during the span of 3 decades demonstrated increased risk for cancer and other chronic health problems…
In the Journals Plus

Timing between thyroidectomy, radioactive iodine does not affect DTC outcomes

August 29, 2016
Disease outcomes in differentiated thyroid cancer, or DTC, are not influenced by the time between total thyroidectomy and radioactive iodine dosing, study data show. …
More News Headlines »
CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Video
Meeting News Coverage

VIDEO: Use of checkpoint inhibitors has advanced the treatment of cancer

August 5, 2016
More »
Featured
Discoveries from ASCO 2016: Breast Cancer

Discoveries from ASCO 2016: Breast Cancer

CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today